Merge Extends Customer Base - Analyst Blog
February 13 2013 - 9:30AM
Zacks
Imaging and interoperability
solutions provider Merge Healthcare Incorporated
(MRGE) has extended its customer base as it seeks to provide its
complete cardiology solutions suite to Arnot Ogden Medical Center,
a member of Arnot Health.
The Merge cardiology suite consists of Merge Cardio and Merge Hemo.
While Merge Cardio is an enterprise level image and information
system which delivers a patient’s complete cardio record across all
cardiac modalities, Merge Hemo automates the cath lab process into
an electronic record to enable automated reporting. In Dec 2012,
Merge Hemo was selected as Category Leader in the Best in KLAS
Awards for 2012 in the realm of Software and Services for
Cardiology Hemodynamics. This marked the second year that Merge’s
offering has won this award.
The deployment of Merge’s solutions at Arnot Ogden will enable the
latter to improve standards of care as it will capture, manage and
display multi-modality cardiac images and hemodynamics and ECG data
across the enterprise. The implementation of the complete
cardiology suite will increase image access and exchange while
decreasing healthcare costs at Arnot Ogden.
Management at Arnot Ogden assert that the deployment of Merge
Cardio will enhance workflow efficacy and improve time management
for physicians. Further, the implementation of Merge Hemo is
expected to augment quality control, helped by upgraded
organizational environment.
Our Take
It is commendable that Merge has effectively expanded its client
base amid a tough reimbursement environment for advanced medical
imaging. We are also encouraged by the impressive growth in recent
quarters on the back of client wins despite the general slowdown in
hospital spending and low demand for imaging equipment and related
technology.
Going forward, we are bullish on Merge as it has immense potential
in the diagnostic imaging market. As a result, the stock carries a
Zacks Rank #2 (Buy). Besides Merge, medical stocks like
ResMed (RMD), Medical Action
(MDCI) and MedAssets Inc (MDAS), carrying a Zacks
Rank #1 (Strong Buy) are expected to do well in the near term.
MEDASSETS INC (MDAS): Free Stock Analysis Report
MEDICAL ACTION (MDCI): Free Stock Analysis Report
MERGE HEALTHCAR (MRGE): Free Stock Analysis Report
RESMED INC (RMD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Mirage Energy (PK) (USOTC:MRGE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Mirage Energy (PK) (USOTC:MRGE)
Historical Stock Chart
From Jul 2023 to Jul 2024